Võrdle meetodeid

	Psoriaatilise artriidi elukvaliteedi skaala (PsAQoL)	Bath'i anküloseeriva spondüliidi funktsionaalne indeks (BASFI)	Disease Activity Score 28-Joint (DAS28)
Valdkond	Reumatoloogia	Reumatoloogia	Reumatoloogia
Perekond	Process / pipeline	Process / pipeline	Process / pipeline
Tekkeaasta	1997	1994	1995
Looja	McKenna & Doherty	Calin et al.	Prevoo et al.
Tüüp	Patient-reported outcome (PRO)	Patient-reported outcome (PRO)	Clinician-rated
Algallikas	Soderlin MK, Bergman S. Psychometric properties of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument: Rasch analysis. Arthritis Care Research. 2011;63(11):1589-1595.	Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. The Journal of Rheumatology. 1994;21(12):2281-2285.	Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48.
Rööpnimetused	PsAQoL, PSAQoL	BASFI, BAS-FI	DAS28, DAS28-CRP, DAS28-ESR
Seotud	4	4	3
Kokkuvõte	The PsAQoL is a disease-specific patient-reported outcome measure of quality of life impact in psoriatic arthritis (PsA), a chronic inflammatory condition affecting joints and skin. Developed by McKenna and Doherty in 1997, PsAQoL comprises 20 items assessing the multidimensional impact of PsA on physical function, emotional well-being, work productivity, and social participation. PsAQoL captures the patient's lived experience of the disease, complementing clinical disease activity measures (CRP, joint counts) and providing a holistic view of treatment benefit in PsA research and practice.	The BASFI is a patient-reported outcome measure of functional disability in ankylosing spondylitis (AS), assessing physical limitations in 10 common daily activities. Introduced by Calin et al. in 1994, BASFI measures the impact of AS on quality of life and functional capacity, complementing BASDAI (disease activity). While BASDAI reflects inflammatory burden, BASFI reflects the consequences of inflammation and spinal damage on a patient's ability to perform daily tasks. BASFI is used alongside BASDAI in AS management to capture both disease activity and its functional impact.	The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden.